Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease

Clinical Pharmacokinetics

Volumn 31, Issue 5, 1996, Pages 386-406

  Hatlebakk, Jan Gunnar ^a,b   Berstad, Arnold ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; ANTACID AGENT; CIMETIDINE; CISAPRIDE; DOMPERIDONE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOCLOPRAMIDE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; ROXATIDINE; SUCRALFATE;

AREA UNDER THE CURVE; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MOTILITY; HUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STOMACH ACID SECRETION;

EID: 0029860237     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199631050-00005     Document Type: Review

References (131)

1. Bell NJV, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 Suppl. 1: 59-67
2. Graham DY, Smith JL, Patterson DJ. Why do apparently healthy people use antacid tablets? Am J Gastroenterol 1983; 78: 257-60
3. Lambert JR, Kormann MG, Nicholson L, et al. In-vivo anti-reflux and raft properties of alginates. Aliment Pharmacol Therap 1990; 4: 615-22
4. Johnson LF, DeMeester TR. Evaluation of elevation of the head of the bed, bethanechol and antacid form tablets on gastro-oesophageal reflux. Dig Dis Sci 1981; 19: 169-76
5. Weberg R, Berstad K, Berstad A. Acute effects of antacids on gastric juice components in duodenal ulcer patients. Eur J Clin Invest 1990; 20: 511-5
6. Weberg R, Berstad A, Osnes M. Comparison of low-dose antacids, cimetidine, and placebo on 24 hour intragastric acidity in healthy volunteers. Dig Dis Sci 1992; 37: 1810-4
7. Weberg R, Berstad A. Gastrointestinal absorption of aluminium from single doses of aluminium containing antacids in man. Eur J Clin Invest 1986; 16: 428-32
8. Laitinen S, Ståhlberg M, Kairaluoma MI, et al. Sucralfate and alignate/antacid in reflux esophagitis. Scand J Gastroenterol 1985; 20: 229-32
9. Hameeteman W, Van de Boomgaard DM, Dekker W, et al. Sucralfate versus cimetidine in reflux esophagitis: a single-blind multicenter study. J Clin Gastroenterol 1987; 9: 390-4
10. Carling L, Cronstedt J, Engquist A, et al. Sucralfate versus placebo in reflux esophagitis: a double blind multicenter study. Scand J Gastroenterol 1988; 23: 1117-24
11. Haram E-M, Weberg R, Berstad A. Urinary excretion of aluminium after ingestion of sucralfate and an aluminium-containing antacid in man. Scand J Gastroenterol 1987; 22: 615-8
12. Robertson JA, Salusky IB, Goodman WG, et al. Sucralfate. intestinal aluminium absorption, and aluminium toxicity in a patient on dialysis. Ann Intern Med 1989; 111: 179-81
13. Inauen W, Emde C. Weber B, et al. Effects of ranitidine and cisapride on acid reflux and oesophageal motility in patients with reflux oesophagitis: a 24 hour ambulatory combined pH and manometry study. Gut 1993; 34: 1025-31
14. Albihi R, McCallum RW. Metoclopramide: pharmacology and clinical application. Ann Intern Med 1983; 98: 86-95
15. Durazo FA, Valenzuela JE. Effect of single and repeated doses of metoclopramide on the mechanisms of gastroesophageal reflux. Am J Gastroenterol 1993; 88: 1657-62
16. Quigley EMM. Gastroesophageal reflux disease: the role of motility in pathophysiology and therapy. Am J Gastroenterol 1993; 88: 1649-50
17. Bakke OM, Segura J. The absorption and excretion of metoclopramide in three different animal species. J Pharmacol 1976; 28: 32-9
18. Bateman DN, Gokal R, Dodd TRP, et al. the pharmacokinetics of single doses of metoclopramide in renal failure. Eur J Clin Pharmacol 1981; 19: 437-41
19. Miller LG, Jankovic J. Metoclopramide-induced movement diorders: clinical findings with a review of the litterature. Arch Int Med 1989; 149: 2486
20. Robinson OPW. Metocopramide: side effects and safety. Postgrad Med J 1973; 49 Suppl. 4: 77-80
21. Heykants J, Hendriks R, Meuldermans W, et al. On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bio-availability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokinet 1981; 6: 61-70
22. Meuldermans W, Hurkmans R, Swysen E, et al. On the pharmacokinetics of domperidone in animals and man. III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man. Eur J Drug Metab Pharmacokinet 1981; 6: 49-60
23. Brogden RN, Carmine AA, Heel RC, et al. Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronicdyspepsia and as an antiemetic. Drugs 1982; 24: 360-400
24. Wienheck M, Li Q. Cisapride in gastro-oesophageal reflux disease: Effects on oesophageal motilkity and intra-oesophageal pH. Scand J Gastroenterol 1989; 24 Suppl. 165: 13-8
25. Gilbert RJ, Dodds WJ, Kahrilas PJ, et al. Effects of cisapride, a new prokinetic agent, on esophageal motor function. Dig Dis Sci 1987; 32: 1331-6
26. Corazziari E, Bontempo I, Anzini F. Effect of cisapride on primary peristalsis and lower esophageal sphincter pressure Dig Dis Sci 1984; 34: 1600-5
27. Ceccatelli P, Janssens J, Vantrappen G, et al. Cisapride restores the decreased lower oesophageal sphincter pressure in reflux patients. Gut 1988; 29: 631-5
28. Bost R, Hostein J, Carpentier P. et al. Effects of cisapride on motility patterns in systemic sclerosis. Eur J Gastroenterol Hepatol 1992; 4: 323-8
29. Smout AJPM, Bogaard JW, Grade AC, et al. Effects of cisapride, a new gastrointestinal prokinetic substance, on interdigestive and postprandial motor activity of the distal oesophagus in man. Gut 1985; 26: 246-51
30. Collins BJ, Spence RAJ, Ferguson R, et al. Cisapride: influence on oesophagesl and gastric emptying and gastro-oesophageal reflux in patients with reflux oesophagitis. Hepatogastroenterology 1987; 34: 113-6
31. Baldi F, Ferrarini F, Longanesi A, et al. Effect of short-term cisapride treatment on gastro-oesophageal reflux disease. Prog Med 1987; 43 Suppl. 1: 29-34
32. Van Peer A, Verlinden M, Woestenborghs R, et al. Clinical pharmacokinetics of cispride. In: Johnson AG, Lux G, editors. Progress in the treatment of gastrointestinal motility disorders; the role of cisapride. Amsterdam: Excerpta Medica, 1988: 23-9
33. McCallum RW, Prakash C, Campoli-Richards DM. et al. Cisapride: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prookinetic agent in gastrointestinal motility disorders. Drugs 1988; 36: 652-81
34. Stanghellini V, Corinaldesi R, Barbara L. Effects of different dosage schedules of cisapride on gastric emptying in ideopathic gastroparesis. In: Heading RC, Wood JD, editors. Gastrointestinal dysmotility: focus on cisapride. New York: Raven Health Care Communications, 1992: 197-200
35. Meuldermans W, Van Peer A, Hendrickx J. et al. Excretion and biotransformation of cisapride in dogs and humans after oral administration. Drug Metab Dispos 1988; 16: 403-9
36. Collen MJ, Lewis JH, Benjamin SB. Gastric acid hypersecretion in refractory gastroesphageal reflux disease. Gastroentrology 1990; 98: 654-61
37. Merki HS, Witzel L, Walt RP, et al. Double blind comparison of the effects of cimetidine. ranitidine, famotidine, and placebo on intragastric acidity in 30 normal volunteers, Gut 1988; 29: 81-4
38. Berstad A, Rydning A, Kolstad B, et al. Reduction of postprandial gastric acidity and pepsin concentration by ranitidine and antacids in healthy volunteers. Scand J Gastroenterol 1981; 16 Suppl. 69: 67-73
39. Frislid K, Berstad A. Prolonged influence of a meal on the effect of ranitidine. Scand J Gastroenterol 1984; 19: 429-32
40. Frislid K, Guldvog I, Berstad A. Kinetics of the inhibition of food-stimulated secretion by ranitidine in dogs. Eur Surg Res 1985; 17: 360-5
41. Hatlebakk JG, Berstad A. Gastro-oesophageal reflux during three months of therapy with ranitidine in reflux oesophagitis. Scand J Gastroenterol 1996. In press
42. Berstad A, Frislid K, Rydning A. Relationship between rantidine plasma levels and reduction of postpradial intragatric acidity in healthy man. Scand J Gastroenterol 1982; 17: 109-12
43. Nwokolo CU, Smith JTL, Gavey C, et al. Tolerance during 29 days of conventional dosing with cimetidine. nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther 1990; 4 Suppl. 1: 29-46
44. 2-receptor antagonists. Aliment Pharmacol Ther 1990; 4 Suppl. 1: 15-28
45. Hurlimann S, Abbühl B, Inauen W, et al. Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. Aliment Pharmacol Ther 1994; 8: 193-201
46. Prewett EJ, Hudson M, Nwokolo CU, et al. Nocturnal intragastric acidity during and after a period of dosing with either ranitidine or omeprazole. Gastroenterology 1991; 100: 873-7
47. Priehard PJ, Jones DB, Yeomans ND, et al. The effectiveness of ranitidine in reducing gastric acid-secretion decreases with continued therapy. Br J Clin Pharmacol 1986; 22: 663-8
48. Frislid K, Aadland E, Berslad A. Augmented postprandial gastric acid secretion due to exposure of ranitidine in healthy subjects. Scand J Gastroenterol 1985; 21: 119-22
49. Stein DL, Simon TJ, Berlin RG, et al. Controlling 24 hour esophageal acid exposure in patients with healed erosive esophagitis prevents endoscopic recurrence and symptomatic deterioration: results of a 6 month, randomized, donhle-blind. U.S., placebo-controlled trial comparing famotidine 20mg b.i.d. and 40mg b.i.d. Gastroenterology 1991; 100: A167
50. 2-receptor antagonists he taken in an effervescent formulation? Eur J Gastroenterol Hepatol 1991; 3 Suppl. 1: S38
51. Ström M, Madsen S, Norlander B. Intragastric pH rise with effervescent citrate-cimelidine. Lancet 1991; 337: 433
52. Thomson ABR, Babiuk L, Kirdeikis P, et al. A dose-ranging study of ranitidine and its effect on intragastric and intra-oesophageal reflux disease. Aliment Pharmacol Ther 1994; 8: 443-51
53. Jansen JBMJ, Baak LC, Lamers CBHW. Effect of increasing doses of ranitidine on exposure of the esophagus to gastric acid in patients with reflux oesophagitis. Scand J Gastroenterol 1988; 23 Suppl. 154: 2-5
54. Orr WC, Robinson MG, Humphries TJ. et al. Dose-response effect of famotidine on patterns of gastro-oesophageal reflux. Aliment Pharmacol Ther 1988; 2: 229-35
55. 2-receptor antagonist, in healthy man. Br J Clin Pharmacol 1975; 2: 481-6
56. Bodemar G, Norlander B, Walan A. Pharmacokinetics of cimetidine after single doses and during continuous treatment. Clin Pharmacokinel 1981; 6: 306-15
57. Miller R. Pharmacokinetics and bioavailability of ranitidine in humans. J Pharm Sci 1984; 73: 1376-9
58. Marchant J, Summers K, Reed PI, et al. Ranitidine pharmacokinetics: Effect of administration time and food. Gastroenterology 1987; 92: 1516
59. Lebert PA, MacLeod SM, Mahon WA, et al. Ranitidine kinetics and dynamics. I. Oral dose studies. Clin Pharmacol Ther 1981; 30: 539-44
60. Brater DC, Peters MN, Eshelman FN, et al. Clinical comparison of cimetidine and ranitidine. Clin Pharmacol Ther 1982; 32: 484-9
61. 2-receptor antagonist, Int J Clin Pharmacol Ther Toxicol 1984; 22: 214-7
62. Lin JH, Chremos AN, Yeh KC, et al. Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man. Eur J Clin Pharmacol 1988; 34: 41-6
63. Kroemer H, Klotz. Pharmacokinetics of famotidine in man. J Clin Pharmacol Ther Toxicol 1987; 25: 458-63
64. Yeh KC, Chremos AN, Lin JH, et al. Single dose pharmacokinetics and bioavailability of famotidine in man: results of multicenter collaborative studies. Biopharm Drug Dispos 1987; 8: 549-60
65. Aronoff GR, Sloan RS, Bopp RJ, et al. Nizatidine kinetics in patients with renal insufficiency. Clin Pharmacol Ther 1986; 39: 178
66. Callaghan JT, Bergstrom RF, Rubin A, et al. A pharmacokinetic profile of nizatidine in man. Scand J Gastroentrol 1987; 22 Suppl. 136; 9-17
67. 2-receptor antagonist, roxatidine acetate, in healthy men. Drugs 1988; 35 Suppl. 3: 53-64
68. Murdoch D, McTavish D. Roxatidine acetate: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders. Drugs 1991; 42: 240-60
69. Lamaire N, Rosenkranz B, Maass L, et al. A pharmacokinetic study of roxatidine acetate in chronic renal failure. Drugs 1988; 35 Suppl. 3: 48-52
70. Howden CW. Clinical pharmacology of omeprazole. Clin Pharmacokinet 1991; 20: 38-49
71. Flouvat B, Delhotal-Landes B, Cournot A, et al. Single and multiple-dose pharmacokinetics of lansoprazole in elderly subjects. Br J Clin Pharmacol 1993; 36: 467-9
72. Delhotal-Landes B, Cournot A, Vermerie N, et al. The effect of food and antacids on lansoprazole absorption and disposition. Eur J Drug Metah Pharmacokinet 1991; (Spec. Iss. III): 315-20
73. + ATPase inhibitor pantoprazole. Gastroenterology 1994; 106: A91
74. Simon B, Müller P, Murinis E, et al. Effect of repeated oral administration on BY1023/SK&F96022 - a new substituted benzimidazole derivative - on pentagastrin-stimulated gastricacid secretion and pharmacokinetics in man. Aliment Pharmacol Ther 1990; 40: 373-80
75. 2receptor Antagonists: 1976 Oct; London. Oxford: Excerpta Medica. 1977: 38-52
76. Bodemar G, Norlander B, Fransson L, et al. The influence of a meal and antacids on cimetidine absorption in patients with peptic ulcer disease. Seand J Gastroenterol 1977; 12 Suppl. 45: 12
77. Spence RW, Creak DR, Celestin LR. Influence of a meal on the absorption of cimetidine. Digestion 1976; 14: 127-32
78. Steinberg WM, Lewis JH. My lama II inhibits the absorption of cimetidine. Gastroenterology 1980; 78: 1269
79. Bodemar G, Mills JG, Norlander B, et al. Effects of antacids on the absorption of cimetidine. Gut 1978; 19: A990
80. Gladziwa U, Klotz U. Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure. Clin Pharmacokinel 1994; 27: 393-408
81. Ma KW, Brown DC, Masler DS, et al. Effects of renal failure on blood levels of cimetidine. Gastroenterology 1978; 74: 473-7
82. Shinn AF. Clinical relevance of cimetidine drug interactions. Drug Saf 1992; 7: 245-67
83. Garg DC, Weidler DJ, Eshelman FN. Ranitidine bioavailability and kinetics in normal male subjects. Clin Pharmacol Ther 1983; 33: 445-52
84. Gugler R, Brand M, Somogyi A. Impaired cimetidine absorption due to antacids and metoclopramide. Eur J Clin Pharm 1981; 20: 225-8
85. Devis G, De Rop H, Du Ville L, et al. Rapid absorption and high plasma concentrations with the ranitidine effervescent formulation results in very quick onset of action on the intragastric pH in volunteers. Scand J Gastroenterol 1993; 28 Suppl. 197: 70
86. Bataille C, Hublé F, Krug F, et al. Runitidine in mild reflux oesophagitis: Comparison of the conventional and the effervescent formulations. Hell J Gastroenterol 1992; 5 Suppl.: 19
87. Mihaly GW, Marino AT, Webster LK, et al. High dose of antacid (Mylanta II) reduces bioavailability of ranitidine. BMJ 1482; 285: 998-9
88. Frislid K, Berstad A. High doses of antacid reduces bioavailability of ranitidine. BMJ 1983; 286: 1358
89. Maconochie JG, Thomas M, Michael MF, et al. Ranitidine sucralfate interaction study. Clin Pharmacol Ther 1987; 41: 205
90. Mullersmann G, Gotz VP, Russell WL, et al. Lack of clinically significant in vitro and in vivo interactions between ranitidine and sucralfate. J Pharmaceut Sci 1986; 75: 995-8
91. Greene DS, Szeego PL, Anslow JA, et al. The effect of age on ranitidine pharmacokinetics. Clin Pharmacol Ther 1986; 39: 300-305
92. Webster LK, Jones DB, Smallwood RA. Influence of cimetidine and ranitidine on ethanol pharmacokinetics. Aust NZ J Med 1985; 15: 359-60
93. Gladziwa U, Krishna DR, Klotz U. et al. Pharmacokinetics of ranitidine in patients undergoing haemofiltration. Fur J Clin Pharmacol 1988; 35: 427-30
94. Lin JH, Chremos AN, Kanovsky SM, et al. Effects of antacids and food on absorption of famotidine. Br J Clin Pharmacol 1987; 24: 551-3
95. Echizen H, Ishizaki T. Clinical pharmacokinetics of famotidine. Clin Pharmacokinet 1991; 21: 178-94
96. Gladziwa U, Klotz U, Krishna DR, et al. Pharmacokinetics and dynamics of famotidine in patients with renal failure. Br J Clin Pharmacol 1988; 26: 315-21
97. Morgan MY, Stamhuk D. Famotidine pharmacokinetics following oral and intravenous administration in patients with liver disease: results of a preliminary study. Postgrad Med J 1986; 62 Suppl. 2: 29-37
98. Schwartz JI, Yeh KC, Berger ML, et al. Novel oral medication delivery system for famotidine. Gut 1994; 35 Suppl. 4: A82
99. 2-blocker nizatidine. Clin Pharm Ther 1987; 42: 514-20
100. Callaghan JT, Rubin A, Knadler MP, et al. Nizatidine. an H2-receptor antagonist: disposition and safety in the elderly. J Clin Pharmacol 1987; 27: 618-24
101. Takeguchi N, Tamiyama Y, Morii M. The intracellular cycling of gastric proton pump is differently affected by E-3810 and lansoprazole in rats. Abstracts II: Poster presentations. Abstract at the World Congresses of Gastroenterologe; 1994 Oct 2-7; Los Angeles.
102. Hatlebakk JG, Berstad A, Carling L, et al. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Scand J Gastroenterol 1993; 28: 224-8
103. Tolman KG, Sanders SW, Buchi KN. Gastric pH levels after 15mg and 30mg of lansoprazole and 20mg omeprazole. Gastroenterology 1994; 106: A197
104. Howden CW, Meredith PA, Forrest JAH, et al. Oral pharmacokinetics of omeprazole. Eur J Clin Pharm 1984; 26: 641-3
105. Pilbrant Å. Cederherg C. Development of an oral formulation of omeprazole. Scand J Gastroenterol 1985; 20 Suppl. 108: 113-20
106. Sutfin T, Baliner K, Boström H, et al. Stereoslective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989; 11: 176-84
107. Olbe L, Cederberg C, Lind T. et al. Effect of omeprazole on gastric acid secretion and plasma gastrin in man. Scand J Gastroenterol 1988; 24 Suppl. 166: 27-32
108. Delhotal-Landes B, Petite J-P. Flouvat B. Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 1995; 28: 458-70
109. Hussein Z, Isenberg JI, Grannemann GR. Pharmacokinetics of lansoprazole in young to middle-aged and elderly subjects following single and multiple doses of 15 and 30mg. Pharm Res 1991; 8 Suppl.: S301
110. Delhotal-Landes B, Flouvat B, Duchier J, et al. Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. Eur J Clin Pharm 1993; 45: 367-71
111. Coste T, Logeais C, Delhotal-Landes B, et al. Pharmacokinetics of lansoprazole after repeated administration in cirrhosis patients. Gastroenterology 1993; 104: A59
112. Hongo M, Ohara S, Hirasawa Y, et al. Effect of lansoprazole on intragastric pH. Comparison between morning and evening dosing. Dig Dis Sci 1992; 37: 882-90
113. Delhotal-Landes B, Cournot A, Vermerie M, et al. The effect of antacid and food on the bioavailability of lansoprazole in man. Eur J Drug Metab Pharmucokinet 1990; 15 Suppl.: 6
114. Moules I, Garrett A, Brocklebank D, et al. Gastric acid inhibition by the proton pump inhibitor lansoprazole is unaffected by food. Br J Clin Res 1993; 4: 153-61
115. Blum RA, Hunt RH, Kidd SL, et al. Pharmacodynamics of various doses of lansoprazole. Am J Gastroenterol 1994; 89: 1634
116. Hogan DL, Koss MA, Feitelberg S, et al. Single and repetitive administration of lansoprazole: effects on gastric acid secretion, pharmacokinetics and serum gastrin in old versus young subjects. Gastroenterology 1991; 100: A84
117. Pue MA, Laroche J, Meineke I, et al. Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. Eur J Clin Pharmacol 1993; 44: 575-8
118. Reill L, Erhardt F, Heinzerling H, et al. Dose response pf pantoprazole 20, 40, 80mg on 24-hour intragstric pH, serum pantoprazole and serum gastrin in man. Gastroenterology 1994; 106: A165
119. Lins RL, De Clerq I, Hartmann M, et al. Pharmacokinetics of the proton pump inhibitor pantoprazole in patients with severe renal impairment. Gastroenterology 1994; 106: A126
120. Middle MV, Müller FO, Mogilnicka EM, et al. Pantoprazole does not impair the efficacy of hormonal contraception. Gastroenterology 1994; 106: A139
121. +-ATPase inhibitor pantoprazole does not influence the pharmacokinetics of phenytoin in man. Gastroenterology 1994; 106: A144
122. Müller FO, Middle MV, Duurseema L, et al. Pantoprazole does not interact with warfarin in man. Gastroenterology 1994; 106: A144
123. Lacey Smith J, Opekun Ar, Larkai E, et al. Sensitivity of the esophageal musoca to pH in gastro-esophageal reflux disease. Gastroenterology 1989; 96: 683-9
124. Echizen H, Shoda R, Umeda N, et al. Plasma famotidine concentration versus intragastric pH in patients with upper gastrointestinal bleeding and in healthy subjects. Clin Pharmacol Ther 1988; 44: 690-8
125. Lind T, Cederberg C, Ekenved G, et al. Effect of omeprazole (a gstric proton pump inhibitor) on pentagastrin stimulated acid secretion in man. Gut 1983; 24: 270-6
126. Sharma BK, Walt RP, Pounder RE. et al. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut 1984; 25: 957-64
127. McCallum RW, Kline MM, Curry N, et al. Comparative effects of metoclopramide and bethanechol on lower esophageal sphincter pressure in reflux patients. Gastroenterology 1975; 68: 1114-8
128. Wallmark B. Omeprazole: mode of action and effect on acid secretion in animals. Scand J Gastroenterol 1989; 24 Suppl. 166: 12-8
129. Koop H. Metabolic consequences of long term inhibition of acid secretion by omeprazole. Ailment Pharmaeol Ther 1992; 6: 399-406
130. Klinkenberg-Knol EC, Meuwissen SGM. Medical therapy of patients with reflux oesophagitis poorly responsive to H2-receptor antagonist therapy. Digestion 1992; 5 Suppl. 1: 44-8
131. Just R, Gideon RM, Castell DO. Omeprazole resistance in patients with gastro-esophageal reflux disease. Gastroenterology 1994; 106